Beatson Centenary Special Issue

• Select this article
  • Robin Leake

  Editorial

  Endocr Relat Cancer 4 (3) 219-220, doi:10.1677/erc.0.0040219
  • Extract
  • Full Text (PDF)
• Select this article
  • D C Smith

  Sir George Thomas Beatson

  Endocr Relat Cancer 4 (3) 221-222, doi:10.1677/erc.0.0040221
  • Extract
  • Full Text (PDF)
• Select this article
  • H J Stewart

  Ovarian ablation - the last 100 years

  Endocr Relat Cancer 4 (3) 223-227, doi:10.1677/erc.0.0040223
  • Extract
  • Full Text (PDF)
• Select this article
  • R W Blamey

  The introduction of the LHRH agonist, Goserelin (Zoladex) into clinical practice

  Endocr Relat Cancer 4 (3) 229-232, doi:10.1677/erc.0.0040229
  • Extract
  • Full Text (PDF)
• Select this article
  • J Hayward

  The Canadian study - 25 years on

  Endocr Relat Cancer 4 (3) 233-236, doi:10.1677/erc.0.0040233
  • Extract
  • Full Text (PDF)
• Select this article
  • M Baum

  Tamoxifen

  Endocr Relat Cancer 4 (3) 237-243, doi:10.1677/erc.0.0040237
  • Extract
  • Full Text (PDF)
• Select this article
  • R C F Leonard,
  • A Ray,
  • L Lee,
  • T Leonard,
  • and P Hopwood

  Tamoxifen toleration and toxicity

  Endocr Relat Cancer 4 (3) 245-249, doi:10.1677/erc.0.0040245
  • Extract
  • Full Text (PDF)
• Select this article
  • R Sainsbury

  Timing of surgery and the ovarian cycle

  Endocr Relat Cancer 4 (3) 251-253, doi:10.1677/erc.0.0040251
  • Extract
  • Full Text (PDF)
• Select this article
  • T J Powles

  Chemoprevention of breast cancer using tamoxifen

  Endocr Relat Cancer 4 (3) 255-260, doi:10.1677/erc.0.0040255
  • Extract
  • Full Text (PDF)
• Select this article
  • M P Vessey and
  • E Daly

  Hormone replacement therapy and the risk of breast cancer: an overview

  Endocr Relat Cancer 4 (3) 261-268, doi:10.1677/erc.0.0040261
  • Extract
  • Full Text (PDF)
• Select this article
  • J Marsden and
  • N P M Sacks

  Hormone replacement therapy and breast cancer

  Endocr Relat Cancer 4 (3) 269-279, doi:10.1677/erc.0.0040269
  • Extract
  • Full Text (PDF)
• Select this article
  • J Cuzick

  The use of hormone replacement therapy for women with breast cancer: a trial in the advanced disease setting

  Endocr Relat Cancer 4 (3) 281-283, doi:10.1677/erc.0.0040281
  • Extract
  • Full Text (PDF)
• Select this article
  • R D Bulbrook,
  • B S Thomas,
  • and D Y Wang

  A retrospective view of androgen and corticoid metabolites in the aetiology and clinical course of breast cancer

  Endocr Relat Cancer 4 (3) 285-288, doi:10.1677/erc.0.0040285
  • Extract
  • Full Text (PDF)
• Select this article
  • R Leake

  Prediction of hormone sensitivity - the receptor years and onwards

  Endocr Relat Cancer 4 (3) 289-296, doi:10.1677/erc.0.0040289
  • Abstract
  • Full Text (PDF)
• Select this article
  • R I Nicholson,
  • J M W Gee,
  • M E Harper,
  • IO Ellis,
  • P Willsher,
  • and J F R Robertson

  erbB signalling in clinical breast cancer: relationship to endocrine sensitivity

  Endocr Relat Cancer 4 (3) 297-305, doi:10.1677/erc.0.0040297
  • Abstract
  • Full Text (PDF)
• Select this article
  • W R Miller

  Uptake and synthesis of steroid hormones by the breast

  Endocr Relat Cancer 4 (3) 307-311, doi:10.1677/erc.0.0040307
  • Extract
  • Full Text (PDF)
• Select this article
  • M Dowsett

  Aromatase inhibitors: current status and future applications

  Endocr Relat Cancer 4 (3) 313-321, doi:10.1677/erc.0.0040313
  • Extract
  • Full Text (PDF)
• Select this article
  • A Purohit,
  • L J Duncan,
  • D Y Wang,
  • N G Coldham,
  • M W Ghilchik,
  • and M J Reed

  Paracrine control of oestrogen production in breast cancer

  Endocr Relat Cancer 4 (3) 323-330, doi:10.1677/erc.0.0040323
  • Abstract
  • Full Text (PDF)
• Select this article
  • M S Morton,
  • N Bundred,
  • D F McMichael-Phillips,
  • C Harding,
  • R I Nicholson,
  • and K Griffiths

  Phyto-oestrogens and breast cancer

  Endocr Relat Cancer 4 (3) 331-339, doi:10.1677/erc.0.0040331
  • Extract
  • Full Text (PDF)
• Select this article
  • C Knabbe,
  • A Kopp,
  • V Müller,
  • S Brandt,
  • E Dietz,
  • P Nollau,
  • and G Zugmaier

  Endocrine aspects of autocrine and paracrine growth control within the breast

  Endocr Relat Cancer 4 (3) 341-349, doi:10.1677/erc.0.0040341
  • Extract
  • Full Text (PDF)
• Select this article
  • A E Wakeling,
  • A J Barker,
  • D H Davies,
  • D S Brown,
  • L R Green,
  • S A Cartlidge,
  • and J R Woodburn

  New targets for therapeutic attack

  Endocr Relat Cancer 4 (3) 351-355, doi:10.1677/erc.0.0040351
  • Extract
  • Full Text (PDF)
• Select this article
  • R L Sutherland,
  • O W J Prall,
  • K M Alle,
  • N R C Wilcken,
  • R Hui,
  • J R Ball,
  • B Sarcevic,
  • S M Henshall,
  • E A Musgrove,
  • and C K W Watts

  Cyclin-dependent kinases as downstream targets of oestrogen action: potential prognostic indicators and therapeutic targets

  Endocr Relat Cancer 4 (3) 357-370, doi:10.1677/erc.0.0040357
  • Extract
  • Full Text (PDF)
• Select this article
  • A Howell,
  • R B Clarke,
  • and E Anderson

  Oestrogens, Beatson and endocrine therapy

  Endocr Relat Cancer 4 (3) 371-380, doi:10.1677/erc.0.0040371
  • Extract
  • Full Text (PDF)
• Select this article
  • P Soutter

  Gynaecological advice to breast cancer specialists

  Endocr Relat Cancer 4 (3) 381-385, doi:10.1677/erc.0.0040381
  • Extract
  • Full Text (PDF)